PharmaCyte Biotech Inc (PMCB)

[bulldurham]

Nuvilex had to wait until today to put out the PR because bio's are not allowed to put one out until the paper is published....

These results were published in the Public Library of Science journal (PLOS ONE) on July 16, 2014.

this was a new expanded paper on results of the previous study...

Promising data have been obtained from this treatment protocol in both animal models of pancreatic adenocarcinoma [15] and in a human phase I/II clinical trial where 4 out of 14 patients with pancreatic cancer showed reductions in tumour size while the other 10 patients showed stable disease as well as a considerable survival benefit [16], [22]. Encouraging data using a similar strategy has also been obtained in two immunocompetent mouse models of mammary cancer [14], [23]. Based upon this data, a clinical protocol was developed for the treatment of spontaneously occurring malignant mammary tumours in dogs [24].

The current paper for the first time presents the primary data from the clinical protocol that was previously published [24].


bull